Bioscientia Center for Human Genetics, Ingelheim, Germany.
Institut für Klinische Genetik, Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Genet Med. 2018 Jun;20(6):614-621. doi: 10.1038/gim.2017.155. Epub 2017 Oct 12.
PurposeHearing loss is genetically extremely heterogeneous, making it suitable for next-generation sequencing (NGS). We identified a four-generation family with nonsyndromic mild to severe hearing loss of the mid- to high frequencies and onset from early childhood to second decade in seven members.MethodsNGS of 66 deafness genes, Sanger sequencing, genome-wide linkage analysis, whole-exome sequencing (WES), semiquantitative reverse-transcriptase polymerase chain reaction.ResultsWe identified a heterozygous nonsense mutation, c.6881G>A (p.Trp2294*), in the last coding exon of PTPRQ. PTPRQ has been linked with recessive (DFNB84A), but not dominant deafness. NGS and Sanger sequencing of all exons (including alternatively spliced 5' and N-scan-predicted exons of a putative "extended" transcript) did not identify a second mutation. The highest logarithm of the odds score was in the PTPRQ-containing region on chromosome 12, and p.Trp2294* cosegregated with hearing loss. WES did not identify other cosegregating candidate variants from the mapped region. PTPRQ expression in patient fibroblasts indicated that the mutant allele escapes nonsense-mediated decay (NMD).ConclusionKnown PTPRQ mutations are recessive and do not affect the C-terminal exon. In contrast to recessive loss-of-function mutations, c.6881G>A transcripts may escape NMD. PTPRQ protein would lack only six terminal residues and could exert a dominant-negative effect, a possible explanation for allelic deafness, DFNA73, clinically and genetically distinct from DFNB84A.
听力损失在遗传上具有极高的异质性,非常适合下一代测序(NGS)。我们鉴定了一个四代家族,该家族中有 7 名成员患有从中等到高频的非综合征性轻度至重度听力损失,发病年龄从儿童早期到二十岁出头。
对 66 个耳聋基因进行 NGS、Sanger 测序、全基因组连锁分析、外显子组测序(WES)、半定量逆转录聚合酶链反应。
我们在 PTPRQ 的最后一个编码外显子中发现了一个杂合的无义突变 c.6881G>A(p.Trp2294*)。PTPRQ 与隐性(DFNB84A)而非显性耳聋有关。对所有外显子(包括推测的“扩展”转录体的替代性剪接 5'和 N 扫描预测外显子)进行 NGS 和 Sanger 测序未发现第二个突变。最高对数优势评分位于 12 号染色体上包含 PTPRQ 的区域,并且 p.Trp2294*与听力损失共分离。WES 未从映射区域中鉴定出其他共分离的候选变体。患者成纤维细胞中的 PTPRQ 表达表明突变等位基因逃避了无意义介导的衰变(NMD)。
已知的 PTPRQ 突变是隐性的,不影响 C 末端外显子。与隐性失活突变相反,c.6881G>A 转录本可能逃避 NMD。PTPRQ 蛋白将仅缺失六个末端残基,并可能发挥显性负效应,这可能是等位基因性耳聋 DFNA73 的解释,在临床上和遗传上与 DFNB84A 不同。